What You Should Know:
- PreciseDx, a pioneering company in oncology diagnostics utilizing artificial intelligence (AI) raises $20.7M in Series B funding led by Eventide Asset Management with participation from Labcorp, Quest Diagnostics, GenHenn Capital Venture, and existing investors. This brings the company's total funding to date to $31.5M.
- The new funding will enable PreciseDx to accelerate its growth and expand its operations. The company plans to invest in talent
Read More
Oncology Platform
Thyme Care Secures $95M to Expand Value-Based Cancer Care Platform
What You Should Know:
- Thyme Care, a leading value-based cancer care enabler raises $95M in funding capital led by Concord Health Partners, with participation from existing investors including CVS Health® Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Foresite Capital, and new investor SignalFire. The funding brings Thyme Care's total funding to $178M.
- Thyme Care is a value-based cancer care enabler focused on improving patient outcomes and
Read More
Pangea Biomed’s ENLIGHT-DP Predicts Cancer Treatment Response from Simple Scans
What You Should Know:
- Pangea Biomed, a leader in precision oncology, announced a significant breakthrough in its ENLIGHT cancer response predictor. A new study published in Nature Cancer demonstrates the effectiveness of their ENLIGHT-DP platform, revealing its ability to predict cancer treatment response across various types and drugs using only routine pathology slides.
- While these findings are promising, further validation and testing are planned for regulatory
Read More
COTA and FDA Extend Collaboration to Advance Use of Real-World Data in Cancer Research
What You Should Know:
- COTA, a leader in real-world data and analytics solutions, today announced a five-year extension of its research collaboration with the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE).
- The five-year extension builds upon a successful partnership established in 2018 and signifies a continued commitment to utilizing real-world data (RWD) to enhance cancer treatment and regulatory decisions.
Building on a Successful
Read More
Guardant Health, Flatiron Health Integrate Genomic Profiling Tests into OncoEMR® Platform
Ibex Medical Analytics Raises $55M to Drive AI for Cancer Diagnosis Adoption Globally
What You Should Know:
– Ibex Medical Analytics (Ibex), a provider of AI-powered cancer diagnostics raises $55M in Series C financing round led by 83North.
- The round also included participation from Sienna Venture Capital and existing investors in the company, Octopus Ventures, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital. The financing brings total funding to over $100M since Ibex’s inception in 2016.
Read More
Oncology Software: The Digital Backbone of Cancer Care
The complex and dynamic landscape of multimodal cancer care is boosting demand for oncology-specific technological innovations. The need for elevated cancer care is steadily climbing, compelling software developers to create increasingly integrated and sophisticated solutions. Oncology has always been at the forefront of digitization due to the substantial amount of data needed and generated for each patient during the treatment process. Today, advanced oncology software offers clinicians a
Read More
C2i Genomics & AstraZeneca Partner to Advance Cancer Therapy
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a strategic collaboration with AstraZeneca, a global life sciences and pharmaceutical leader.
- The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers.
- Expanding on a completion of AstraZeneca’s accelerator BeyondBio SCALE program for start-ups and successful technology validation, C2i Genomics and AstraZeneca
Read More
Tavros Therapeutics Raises $7.5M to Develop Targeted Cancer Therapies
What You Should Know:
- Tavros Therapeutics, a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities raises $7.5 million in Seed II financing co-led by existing investor Piedmont Capital Investments and new investor KdT Ventures, with participation from Alexandria Venture Investments.
- Tavros launched in 2020 with a $3 million seed financing by Piedmont Capital Investments and a strategic collaboration with Zentalis
Read More
Syapse and Genesis Research Form RWE Partnership in Oncology
What You Should Know:
- Today, Syapse, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases, announced that they have entered into a strategic partnership with Genesis Research.
- This partnership will focus on conducting real-world evidence-based research that supports the development and launch of new and innovative treatments.
- As part of the
Read More
